Expanding the limits of cancer therapies
Hemerion develops novel cancer therapies that blend photonics, medecine and biotechnology. Its first breakthrough technology addresses glioblastoma as a complement to neurosurgery. Its efficacy is currently being evaluated in clinical trials.
Dr Maximilien Vermandel, Hemerion's founder, presents the news perspectives opened up by Hemerion to treat glioblastomas."
We're hiring
Hemerion is looking for a talented regulatory affairs and quality assurance officer.